Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Biologics in Therapy
Published in: Biologics in Therapy 1-2/2014

Open Access 01-12-2014 | Commentary

To the Editor; A Commentary on “Switching From Originator to Biosimilar Human Growth Hormone Using a Dialogue Teamwork: Single-Center Experience From Sweden”

Authors: Mats Ekelund, Christopher Bidad, Roy Gomez

Published in: Biologics in Therapy | Issue 1-2/2014

Login to get access

Excerpt

To the Editor …
Appendix
Available only for authorised users
Literature
1.
Flodmark C-E, Lilja K, Woehling H, Järvholm K. Switching from originator to biosimilar human growth hormone using dialogue teamwork: single-center experience from Sweden. Biol Ther. 2013;3:35–43.PubMedCentralPubMedCrossRef
2.
Romer T, Zabransky M, Walczak M, Szalecki M, Balser S. Effect of switching recombinant human growth hormone: comparative analysis of phase 3 clinical data. Biol Ther. 2011;1:1–14.CrossRef
3.
Ranke MB, Lindberg A, KIGS International Board. Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables. J Clin Endocrinol Metab. 2010;95(3):1229–37.PubMedCrossRef
4.
Hey-Hadavi J, Pleil A, Deeb LC, Fuqua JS, Silverman LA, Reiner B, Newfield R, Rajicic N, Wajrnrajch MP, Cara JF. Ease of use and preference for a new disposable self-injection pen compared with a reusable pen for administering recombinant human growth hormone: a multicenter, 2-month, single-arm, open-label clinical trial in patient-caregiver dyads. Clin Ther. 2010;32(12):2036–47.PubMedCrossRef
5.
Grimberg A, Feudtner C, Gordon CM. Consequences of brand switches during the course of pediatric growth hormone treatment. Endocr Pract. 2012;18:307–16.PubMedCrossRef
Metadata
Title
To the Editor; A Commentary on “Switching From Originator to Biosimilar Human Growth Hormone Using a Dialogue Teamwork: Single-Center Experience From Sweden”
Authors
Mats Ekelund
Christopher Bidad
Roy Gomez
Publication date
01-12-2014
Publisher
Springer Healthcare
Published in
Biologics in Therapy / Issue 1-2/2014
Print ISSN: 2195-5840
Electronic ISSN: 2190-9164
DOI
https://doi.org/10.1007/s13554-014-0015-3

Other articles of this Issue 1-2/2014

Biologics in Therapy 1-2/2014 Go to the issue

Original Research

Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting

Erratum

Erratum to: Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System

Original Research

Isoagglutinin Reduction in Human Immunoglobulin Products by Donor Screening

Original Research

Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency

Original Research

One-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age

Case Report

Weekly Teriparatide for Delayed Unions of Atypical Subtrochanteric Femur Fractures
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits